B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle

Autor: Jaroslav Brotanek, Ivan Málek, Janka Franeková, Vera Lanska, Radka Kockova, Markéta Hegarová, Milos Kubanek, Vojtech Melenovsky, Ivan Netuka, Josef Kautzner
Rok vydání: 2016
Předmět:
Adult
Male
medicine.medical_specialty
medicine.drug_class
Ventricular Dysfunction
Right
030204 cardiovascular system & hematology
Severity of Illness Index
03 medical and health sciences
0302 clinical medicine
Internal medicine
Natriuretic Peptide
Brain
Severity of illness
medicine
Natriuretic peptide
Humans
In patient
cardiovascular diseases
030212 general & internal medicine
Stage (cooking)
Aged
Proportional Hazards Models
Retrospective Studies
Heart Failure
business.industry
Proportional hazards model
Retrospective cohort study
General Medicine
Middle Aged
Clinical Science
Prognosis
medicine.disease
medicine.anatomical_structure
Ventricle
Heart failure
Chronic Disease
cardiovascular system
Cardiology
Female
Heart-Assist Devices
business
human activities
circulatory and respiratory physiology
Zdroj: Croatian Medical Journal
Volume 57
Issue 4
ISSN: 1332-8166
0353-9504
DOI: 10.3325/cmj.2016.57.343
Popis: Aim To assess whether B-type natriuretic peptide (BNP) can serve as a predictor of end-stage chronic heart failure (CHF) in patients with severe systolic dysfunction of the systemic right ventricle (SRV). Methods We performed a retrospective analysis in 28 patients with severe systolic dysfunction of the SRV (ejection fraction 23 ± 6%) who were evaluated as heart transplant (HTx) candidates between May 2007 and October 2014. The primary endpoints of the study (end-stage CHF) were progressive CHF, urgent HTx, and ventricular assist device (VAD) implantation. Plasma BNP levels were measured using a chemiluminescent immunoassay. Results During median follow-up of 29 months (interquartile range, 9-50), 3 patients died of progressive CHF, 5 patients required an urgent HTx, and 6 patients underwent VAD implantation. BNP was a strong predictor of end-stage CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence interval, 1.042-1.117, P
Databáze: OpenAIRE
Externí odkaz: